Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 31,784 shares, a decline of 61.2% from the June 30th total of 81,924 shares. Based on an average daily trading volume, of 9,525 shares, the days-to-cover ratio is presently 3.3 days.
Relief Therapeutics Stock Performance
RLFTF opened at $0.20 on Monday. Relief Therapeutics has a 1-year low of $0.16 and a 1-year high of $4.88. The firm’s 50 day simple moving average is $0.35 and its two-hundred day simple moving average is $0.73.
Relief Therapeutics Company Profile
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
See Also
- Five stocks we like better than Relief Therapeutics
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
